Your session is about to expire
← Back to Search
Study Summary
This trial will test whether CC-90011 can make tumors sensitive to anti-hormonal therapy again by inducing androgen receptor expression.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: CC-90011 in combination with Abiraterone and Prednisone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has CC-90011 been the focus of prior scientific exploration?
"Presently, there are 366 ongoing trials involving CC-90011 with a hundred of those in the final phase. While most experiments concerning this drug are based out of Duarte, California, over 17 thousand sites worldwide have started research into this medication."
What is the cutoff for participants being allowed to join this research endeavor?
"Affirmative. According to clinicaltrials.gov, this medical research is still in the recruitment process. It was initially posted on July 28th 2021 and recently updated on July 21st 2022. The study requires 10 patients from a single site."
To what medical conditions is CC-90011 typically prescribed?
"CC-90011 is a therapeutic agent used to treat thyroiditis and other maladies including ulcerative colitis, cancerous growths, and varicella-zoster virus acute retinal necrosis."
To what extent do the risks of CC-90011 outweigh its potential advantages?
"CC-90011 is a relatively new medication, so its safety score was assessed at 1. This reflects the fact that there are only limited clinical data supporting both efficacy and safety in this Phase 1 trial."
Is there any vacancy for participants in this trial?
"According to the clinicaltrials.gov records, this study has been recruiting since its inception on July 28th 2021 and is still actively enrolling patients as of the latest update dated July 21st 2022."
Share this study with friends
Copy Link
Messenger